(Q35623323)

9 August 2017

1 reference

title

Preventative and therapeutic vaccines for cervical cancer (English)

1 reference

9 August 2017

1 reference

cervix uterine cancer

1 reference

1

Richard Roden

1 reference

9 August 2017

T-C Wu

2

1 reference

9 August 2017

publication date

1 August 2003

1 reference

Expert Review of Vaccines

9 August 2017

published in

1 reference

9 August 2017

volume

2

1 reference

9 August 2017

issue

4

1 reference

9 August 2017

page(s)

495-516

1 reference

Papillomaviruses and cancer: from basic studies to clinical application

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.4.495

A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.4.495

Definition of linear antigenic regions of the HPV16 L1 capsid protein using synthetic virion-like particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.4.495

Synthesis and assembly of virus-like particles of human papillomaviruses type 6 and type 16 in fission yeast Schizosaccharomyces pombe

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.4.495

L1-specific protection from tumor challenge elicited by HPV16 virus-like particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.4.495

Immunology of the human papilloma virus in relation to cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.4.495

Genital papillomavirus infection and cervical dysplasia--opportunistic complications of HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.4.495

The dendritic cell system and its role in immunogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.4.495

Developmental regulation of MHC class II transport in mouse dendritic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.4.495

New insights into the mobilization and phagocytic activity of dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.4.495

Intra-epithelial vaccination with COPV L1 DNA by particle-mediated DNA delivery protects against mucosal challenge with infectious COPV in beagle dogs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.4.495

Oral vaccination of mice with human papillomavirus virus-like particles induces systemic virus-neutralizing antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.4.495

NHPV16 VLP vaccine induces human antibodies that neutralize divergent variants of HPV16.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.4.495

Strategies for HPV prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.4.495

Nasal immunization of mice with peptide having a cross-neutralization epitope on minor capsid protein L2 of human papillomavirus type 16 elicit systemic and mucosal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.4.495

Enhanced immunogenicity of a recombinant genital warts vaccine adjuvanted with monophosphoryl lipid A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.4.495

Construction and characterisation of a recombinant vaccinia virus expressing human papillomavirus proteins for immunotherapy of cervical cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.4.495

A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.4.495

Clinical studies of human papilloma vaccines in pre-invasive and invasive cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.4.495

Recombinant adeno-associated virus expressing human papillomavirus type 16 E7 peptide DNA fused with heat shock protein DNA as a potential vaccine for cervical cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.4.495

Sindbis virus: an efficient, broad host range vector for gene expression in animal cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.4.495

Eradication of established HPV16-transformed tumours after immunisation with recombinant Semliki Forest virus expressing a fusion protein of E6 and E7.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.4.495

Immunization strategy against cervical cancer involving an alphavirus vector expressing high levels of a stable fusion protein of human papillomavirus 16 E6 and E7.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.4.495

Stable alphavirus packaging cell lines for Sindbis virus and Semliki Forest virus-derived vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.4.495

In vitro gene transfer using human papillomavirus-like particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.4.495

Papillomavirus pseudovirus: a novel vaccine to induce mucosal and systemic cytotoxic T-lymphocyte responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.4.495

Induction of an antibody response in mice against human papillomavirus (HPV) type 16 after immunization with HPV recombinant Salmonella strains.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.4.495

Immune responses induced by BCG recombinant for human papillomavirus L1 and E7 proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.4.495

Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.4.495

Detection of T helper responses, but not of human papillomavirus-specific cytotoxic T lymphocyte responses, after peptide vaccination of patients with cervical carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.4.495

Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.4.495

Cell-free tumor antigen peptide-based cancer vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.4.495

Purification of heat shock protein-peptide complexes for use in vaccination against cancers and intracellular pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.4.495

Heat shock proteins come of age: primitive functions acquire new roles in an adaptive world

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.4.495

A review of human papillomavirus vaccines from basic science to clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.4.495

Heat shock fusion proteins as vehicles for antigen delivery into the major histocompatibility complex class I presentation pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.4.495

Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.4.495

Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.4.495

A new foreign policy: MHC class I molecules monitor the outside world

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.4.495

Recycling MHC class I molecules and endosomal peptide loading

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.4.495

Papillomavirus virus-like particles can deliver defined CTL epitopes to the MHC class I pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.4.495

Chimeric papillomavirus-like particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.4.495

Gene vaccination with naked plasmid DNA: mechanism of CTL priming

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.4.495

Nucleic acid vaccines: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.4.495

Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.4.495

A DNA vaccine based on a shuffled E7 oncogene of the human papillomavirus type 16 (HPV 16) induces E7-specific cytotoxic T cells but lacks transforming activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.4.495

Distinctions between bovine herpesvirus 1 and herpes simplex virus type 1 VP22 tegument protein subcellular associations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.4.495

Improving DNA vaccine potency by linking Marek's disease virus type 1 VP22 to an antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.4.495

Enhancing DNA vaccine potency by coadministration of DNA encoding antiapoptotic proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.4.495

Interleukin-12 cDNA skin transfection potentiates human papillomavirus E6 DNA vaccine-induced antitumor immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.4.495

Polynucleotide viral vaccines: codon optimisation and ubiquitin conjugation enhances prophylactic and therapeutic efficacy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.4.495

Codon modified human papillomavirus type 16 E7 DNA vaccine enhances cytotoxic T-lymphocyte induction and anti-tumour activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.4.495

Enhancement of sindbis virus self-replicating RNA vaccine potency by targeting antigen to endosomal/lysosomal compartments

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.4.495

Bone marrow-derived dendritic cells serve as potent adjuvants for peptide-based antitumor vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.4.495

Rapid induction of cytotoxic T-cell response against cervical cancer cells by human papillomavirus type 16 E6 antigen gene delivery into human dendritic cells by an adeno-associated virus vector

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.4.495

Genetically modified bone marrow-derived dendritic cells expressing tumor-associated viral or "self" antigens induce antitumor immunity in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.4.495

Antigen-specific cancer immunotherapy using a GM-CSF secreting allogeneic tumor cell-based vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.4.495

Vaccine regimen for prevention of sexually transmitted infections with human papillomavirus type 16.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.4.495

Combination treatment with intralesional cidofovir and viral-DNA vaccination cures large cottontail rabbit papillomavirus-induced papillomas and reduces recurrences

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.4.495

In vivo anti-papillomavirus activity of nucleoside analogues including cidofovir on CRPV-induced rabbit papillomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.4.495

Human papillomavirus vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.4.495

Vaccination of cattle with the N-terminus of L2 is necessary and sufficient for preventing infection by bovine papillomavirus-4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.4.495

Vaccination with yeast-expressed cottontail rabbit papillomavirus (CRPV) virus-like particles protects rabbits from CRPV-induced papilloma formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.4.495

Studies on vaccination against papillomaviruses: Prophylactic and therapeutic vaccination with recombinant structural proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.4.495

Peptide vaccination with an anchor-replaced CTL epitope protects against human papillomavirus type 16-induced tumors expressing the wild-type epitope

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.4.495

Peptide polymerisation facilitates incorporation into ISCOMs and increases antigen-specific IgG2a production

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.4.495

21 January 2018

Identifiers

DOI

10.1586/14760584.2.4.495

1 reference

9 August 2017

1 reference